Update on compounds in Phase 2 and 3 trials from the Alzheimer's Association International Conference
Studies reported at AAIC demonstrate that biomarkers help predict who will develop cognitive impairment and dementia.
Do blood components really leak across an inflamed blood-brain barrier early on in the development of Alzheimer’s disease? Some GWAS hits and budding neuro-imaging and fluid markers are helping researchers find out.
Researchers at AAIC 2013 report that an individual’s subjective sense of worsening memory could be an important predictor of cognitive impairment and dementia.
A small panel of fluid biomarkers could predict a slow or fast disease course in amyotrophic lateral sclerosis.
Much like people with Alzheimer's, mice modelling the disease experience seizures. New research suggests that APP, and not Aβ, makes their neurons hyperexcitable.
New imaging data suggests degeneration of the fornix could help identify seniors on the verge of cognitive decline.
A new grant opportunity will fund projects aimed at understanding the similarities and differences between biomarkers of Alzheimer’s and Parkinson’s diseases.
It’s Not All About You, Neurons. Glia, Blood, Arteries Shine at Symposium Fluid Markers and Imaging Back Idea of Breached Blood-Brain Barrier In Revival of Parabiosis, Young Blood Rejuvenates Aging Microglia, Cognition Glymphatic Flow, Sleep, microRNA Are ...
Two studies examine factors that heighten the risk for dementia in type 2 diabetes patients. Both highlight depression as a dangerous comorbidity.
Amyloid fibrils seeded by Alzheimer’s brain extracts indicate that Aβ forms specific strains in different individuals.
Speakers at Alzheimer’s conference reviewed planned Phase 1 and prevention trials and preclinical studies.
The latest news on C9ORF72 includes a genetic modifier, various animal models, and a potential treatment to untangle stable, guanine-based structures formed by expanded repeats.
Amyotrophic lateral sclerosis may be inherited more often than previously believed, prompting neurologists to rethink how they define familial versus sporadic disease.
Data from Phase 3 solanezumab and bapineuzumab trials are formally published. Both missed their primary endpoints, but researchers gleaned insights about Alzheimer’s diagnosis and biomarkers, as well as how to proceed with amyloid immunotherapy therapy.